HC Wainwright & Co. maintained its Collegium Pharmaceutical [COLL] rating to the equivalent of Buy but changed the price target to $33.0 from $29, in a research note dated 2021-01-11. That figure represents around a 52.14% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Guggenheim’s analysts assigning the shares to “a Neutral” rating in a research note to investors issued in late May. In addition, there was no change from Needham on October 30, 2019. The rater maintained COLL to “a Buy” but assigned new target price of $25.
Is Collegium Pharmaceutical Inc. [NASDAQ:COLL] a Good Buy Right Now?
It should be noted that COLL technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Buy. The average signal changed from 64% Buy in the last week and compares with 40% Buy in the past month. Data from Collegium Pharmaceutical Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 0.34 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.29 million shares while the medium term average advocated for 50% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.3 million shares.
COLL Price Performance
On Wall Street, Collegium Pharmaceutical Inc. [NASDAQ:COLL] finished Friday’s session down -3.90% at $21.69. The stock went up to $22.97 at the same session while its lowest single day price was $21.55. In the last five days, it saw a rise of about 8.29%, Collegium Pharmaceutical Inc. shares gained by almost 8.29% since the beginning of the year. However, the share price has dropped to as low as -15.24% below its one year high. On 01/08/21, the company shares recorded $22.97, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/05/21, the same year at $18.76. The company’s shares have declined by -6.47% in the past year. The 50-day SMA achieved is $19.24 while the 200-day SMA is $19.04. Volume dropped to 0.47 million from 0.67 million in the previous session.
Collegium Pharmaceutical Inc. [COLL] Valuation Measures
Notably, Collegium Pharmaceutical Inc. [COLL] stock cannot be classified as a good candidate in the listing of underestimated low-priced Drug Manufacturers – Specialty & Generic companies to purchase soonest possible with the prevailing 12-month PE ratio of 43.47. The measure means the stock is exchanging at a premium as compared to the 24.35x trailing earnings of the industry. It can be helpful for investors to consider historical price-sales ratio, more specifically, a 2.53 PS value ratio is reported for the last one year of reported earnings. That is lower than the industry average of 2.89 which means COLL serve an unattractive investment opportunity compared to its competitors.
COLL Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 21.17 level, and in case of violation of this particular level, it will cause more drop to 20.65 level. On the upper level, 23.49 is still the key resistance. The stock may increase to the subsequent resistance at 22.59. The Relative Strength Index (RSI) pinned on the 14-day chart is 63.62, implying a neutral technical stance while the MACD stands at 1.87, meaning price will increase in the next trading period. Percent R indicator moved to 26.75%, implying bullish price movement. Stochastic %K at 86.74% suggest selling the stock.
What is the short interest in Collegium Pharmaceutical Inc.?
Short interest in the Collegium Pharmaceutical Inc. stock has surged, increasing by 0.82 million shares to total 3.92 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 4.74 million, data from Yahoo Finance shows. The decrease of -20.92% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 13.21% of the overall float for the stock.
Collegium Pharmaceutical Inc.’s Biggest Shareholders: Who Owns Collegium Pharmaceutical Inc. [COLL]?
Filings by Janus Capital Management LLC showed that the firm now holds a total of 5,122,359 shares or roughly 14.81% of the outstanding COLL shares. This means their shares have reduced by -14,126 from the 5,122,359 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, BlackRock Fund Advisors updated stake is worth $47,006,313. Details in the latest 13F filings reveal that Eventide Asset Management LLC disposed off their 0.00% stake valued at $44,893,276 while Perceptive Advisors LLC cut theirs at $38,053,677. During the last quarter, Eventide Asset Management LLC liquidated 0 of its shares in Collegium Pharmaceutical Inc. The Camber Capital Management LP’s holdings currently number 2,000,000 shares at $43380000.0. According to the firm’s last 13F report, Rubric Capital Management LP shares in the company at filing stood at 1,926,283 shares, roughly $35,616,973.
COLL Earnings Forecast For The Current Quarter
Collegium Pharmaceutical Inc. [COLL] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $78.26M and an earnings per share of $0.31 for Dec 2020. Looking further ahead, the company is expected to report revenue of $84.5M at an EPS of $0.37 for Mar 2021. The estimates represent upside of 8.90% and 75.12% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
COLL Earnings Estimates For The Current Year
For the financial year, Collegium Pharmaceutical Inc. [NASDAQ:COLL] is expected to bring in revenue of $311.92M. The returns are nearly $15.22 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at 0.87, higher than that of FY19 by $1.55. Estimates put this year’s earnings growth at 227.90%, 74.70% for the next, and at an annual 0.55% over the next 5-year period. As for sales, forecasts are for an increase of 5.10% in the current fiscal year and a further 8.90% over the following year.